← All Vera Therapeutics, INC filings

Vera Therapeutics, INC 8-K filings

NASDAQ
VERA
Vera Therapeutics, INC
8-K: Vera Therapeutics Announces Preliminary Cash Position and Suspends At-the-Market Offering
Vera Therapeutics reported a preliminary cash balance of $160.7 million as of December 31, 2023, and suspended its at-the-market stock offering.
NASDAQ
VERA
Vera Therapeutics, INC
8-K: Vera Therapeutics Announces Positive 72-Week Data for Atacicept in IgA Nephropathy Trial
Vera Therapeutics reported positive 72-week data from its Phase 2b ORIGIN trial, showing atacicept's potential as a disease-modifying treatment for IgA nephropathy.